DynCorp

DynPort Vaccine Company (DVC), a subsidiary of Amentum, is a specialized product development company and contract research organization (CRO) focused on biodefense and infectious diseases. The company primarily manages large-scale drug development programs for the U.S. Department of Defense (DoD) and the Biomedical Advanced Research and Development Authority (BARDA). DVC's expertise encompasses the full spectrum of product development, including preclinical research, clinical trial management, regulatory affairs, and manufacturing oversight. They are particularly recognized for their proficiency in the FDA's "Animal Rule" regulatory pathway, which is essential for developing medical countermeasures against threats where human efficacy trials are unethical. DVC has successfully managed the development of vaccines and therapeutics for high-priority indications such as anthrax, plague, and botulism. As part of the Amentum organization, DVC leverages extensive government contracting experience to deliver critical health security solutions.